AU2012357747B2 - TRPM8 antagonists - Google Patents

TRPM8 antagonists Download PDF

Info

Publication number
AU2012357747B2
AU2012357747B2 AU2012357747A AU2012357747A AU2012357747B2 AU 2012357747 B2 AU2012357747 B2 AU 2012357747B2 AU 2012357747 A AU2012357747 A AU 2012357747A AU 2012357747 A AU2012357747 A AU 2012357747A AU 2012357747 B2 AU2012357747 B2 AU 2012357747B2
Authority
AU
Australia
Prior art keywords
thiazole
carboxylate
ethyl
oxy
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012357747A
Other languages
English (en)
Other versions
AU2012357747A2 (en
AU2012357747A8 (en
AU2012357747A1 (en
Inventor
Andrea Aramini
Gianluca Bianchini
Silvia Bovolenta
Laura Brandolini
Sandro Colagioia
Chiara Liberati
Alessio Moriconi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11194365.0A external-priority patent/EP2606888A1/en
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of AU2012357747A1 publication Critical patent/AU2012357747A1/en
Publication of AU2012357747A8 publication Critical patent/AU2012357747A8/en
Publication of AU2012357747A2 publication Critical patent/AU2012357747A2/en
Assigned to DOMPE' FARMACEUTICI S.P.A. reassignment DOMPE' FARMACEUTICI S.P.A. Amend patent request/document other than specification (104) Assignors: DOMPE' S.P.A.
Application granted granted Critical
Publication of AU2012357747B2 publication Critical patent/AU2012357747B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/40—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/42—One oxygen atom attached in position 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2012357747A 2011-12-19 2012-12-19 TRPM8 antagonists Active AU2012357747B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11194365.0 2011-12-19
EP11194365.0A EP2606888A1 (en) 2011-12-19 2011-12-19 Trpm8 antagonists
EP12178327.8 2012-07-27
EP12178327 2012-07-27
PCT/EP2012/076147 WO2013092711A1 (en) 2011-12-19 2012-12-19 Trpm8 antagonists

Publications (4)

Publication Number Publication Date
AU2012357747A1 AU2012357747A1 (en) 2014-07-10
AU2012357747A8 AU2012357747A8 (en) 2014-07-24
AU2012357747A2 AU2012357747A2 (en) 2014-08-21
AU2012357747B2 true AU2012357747B2 (en) 2017-09-07

Family

ID=47520061

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012357747A Active AU2012357747B2 (en) 2011-12-19 2012-12-19 TRPM8 antagonists

Country Status (22)

Country Link
US (2) US9585875B2 (enExample)
EP (1) EP2793883B1 (enExample)
JP (2) JP6238906B2 (enExample)
KR (1) KR102000319B1 (enExample)
CN (1) CN104220069B (enExample)
AU (1) AU2012357747B2 (enExample)
CY (1) CY1120403T1 (enExample)
DK (1) DK2793883T3 (enExample)
EA (1) EA025356B1 (enExample)
ES (1) ES2676884T3 (enExample)
HR (1) HRP20181086T1 (enExample)
HU (1) HUE038407T2 (enExample)
LT (1) LT2793883T (enExample)
ME (1) ME03038B (enExample)
PL (1) PL2793883T3 (enExample)
PT (1) PT2793883T (enExample)
RS (1) RS57389B1 (enExample)
SI (1) SI2793883T1 (enExample)
SM (1) SMT201800351T1 (enExample)
TR (1) TR201808861T4 (enExample)
WO (1) WO2013092711A1 (enExample)
ZA (1) ZA201404499B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481727A1 (en) * 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
SMT201800351T1 (it) 2011-12-19 2018-09-13 Dompe Farm Spa Antagonisti trpm8
CA2908365C (en) 2013-05-24 2023-02-28 Nestec S.A. Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using linalool
US10294243B2 (en) 2014-06-05 2019-05-21 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pesticides
SI3157918T1 (sl) 2014-06-23 2019-05-31 Dompe Farmaceutici S.P.A. 2-aril-4-hidroksi-1,3-tiazolni derivati, uporabni kot inhibitorji TRPM8 pri zdravljenju nevralgije, bolečine, KOPB in astme
JP6865743B2 (ja) 2015-10-01 2021-04-28 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｔｒｐｍ８の活性調節因子として有用な化合物
EP3184524A1 (en) * 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
JP6943887B2 (ja) 2016-06-13 2021-10-06 田辺三菱製薬株式会社 血管運動症状を治療または予防するための組成物および方法
WO2018117166A1 (ja) * 2016-12-21 2018-06-28 キッセイ薬品工業株式会社 チアゾール誘導体、またはその薬理学的に許容される塩

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153607A (en) * 1977-03-28 1979-05-08 Basf Aktiengesellschaft Process for the production of 4,5-disubstituted thiazoles
US5614520A (en) * 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
EP1321463A1 (en) * 2001-12-21 2003-06-25 Shire Biochem Inc. Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
WO2007089031A1 (en) * 2006-02-01 2007-08-09 Takeda Pharmaceutical Company Limited Piperidine derivatives as tachykinin receptor antagonists
WO2012036233A1 (ja) * 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59220687A (ja) * 1983-05-30 1984-12-12 株式会社日立製作所 直接サイクル型軽水原子炉一次冷却系の腐食環境抑制設備
US20080214654A1 (en) 2004-10-13 2008-09-04 Bayer Healthcare Ag Substituted Benzyloxy-Phenylmethylamide Derivatives
WO2007017094A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted benzyloxy-phenylmethylcarbamate derivatives
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
WO2007080109A1 (en) 2006-01-16 2007-07-19 Bayer Healthcare Ag Substituded benzyloxy-phenylmethylurea derivatives
CA2651865C (en) 2006-05-10 2015-11-24 Janssen Pharmaceutica N.V. Cold menthol receptor-1 antagonists
EP2183239B1 (en) 2007-07-18 2012-08-22 Janssen Pharmaceutica, N.V. Sulfonamides as trpm8 modulators
US8148422B2 (en) * 2008-12-18 2012-04-03 Janssen Pharmaceutica, Nv Sulfonamides as TRPM8 modulators
WO2010103381A1 (en) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Spirocyclic piperidine derivatives as trpm 8 modulators
US20120094964A1 (en) * 2009-05-01 2012-04-19 Tadashi Inoue Sulfamoyl benzoic acid derivatives as trpm8 antagonists
SMT201800351T1 (it) 2011-12-19 2018-09-13 Dompe Farm Spa Antagonisti trpm8

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153607A (en) * 1977-03-28 1979-05-08 Basf Aktiengesellschaft Process for the production of 4,5-disubstituted thiazoles
US5614520A (en) * 1990-11-30 1997-03-25 Teijin Limited 2-arylthiazole derivatives and pharmaceutical composition thereof
EP1321463A1 (en) * 2001-12-21 2003-06-25 Shire Biochem Inc. Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
WO2007089031A1 (en) * 2006-02-01 2007-08-09 Takeda Pharmaceutical Company Limited Piperidine derivatives as tachykinin receptor antagonists
WO2012036233A1 (ja) * 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
CAS RN 1240597-62-9; STN entry date: 13 September 20104-Ethoxy-2-phenyl-5-oxazolecarboxylic acid *
CAS RN 1240603-12-6; STN entry date: 13 September 20104-Amino-2-phenyl-5-oxazolecarboxamide *
CAS RN 1240614-30-5; STN entry date: 13 September 20104-Amino-2-phenyl-5-oxazolecarbonitrile *
CAS RN 1240614-44-1; STN entry date: 13 September 20104-Amino-2-phenyl-5-oxazolecarboxylic acid *
CAS RN 1240614-78-1; STN entry date: 13 September 20104-Amino-2-phenyl-5-oxazolol *
CAS RN 1240617-49-5; STN entry date: 13 September 20104-Ethoxy-2-phenyl-5-oxazolecarbonitrile *
CAS RN 1240617-55-3; STN entry date: 13 September 20104-Ethoxy-2-phenyl-5-oxazolecarboxamide *
CAS RN 1240618-16-9; STN entry date: 13 September 20104-Ethoxy-2-phenyl-5-oxazolol *
CAS RN 262856-07-5; STN entry date: 24 April 20002-(2-chlorophenyl)-4-hydroxy-5-thiazolecarboxylic acid ethyl ester *
CAS RN 263160-35-6; STN entry date: 26 April 20004-[(2,6-Dichlorophenyl)methoxy]-2-phenyl-5-thiazolecarboxylic acid *
DRIDI, K. et al, Synthetic Communications, 1998, vol. 28, pp. 167-174 *
HERTZOG, D.L. et al, Bioorganic & Medicinal Chemistry Letters, 2006, vol. 16, pp. 4723-4727 *
HOU, R.-S. et al, "Synthesis of 2-Phenylthiazoles from a-Tosyloxyketones and Thiobenzamide in [Bmim][PF6] Ionic Liquid at Ambient Temperature", Journal of the Chinese Chemical Society, 2006, vol. 53, pp. 863-866 *
ILYIN, A.P. et al, Tetrahedron Letters, 2006, vol. 47, pp. 2649-2653 *
KERDESKY, F.A. et al, Journal of Medicinal Chemistry, 1991, vol. 34, pp. 2158-2165 *
RIED, W. et al, "Thiazolsynthesen mit N-Cyanimidsaureestern oder 3-Cyanisoharnstoffen und Thioglycolsaurederivaten", Liebigs Annalen der Chemie, 1986, pp. 780-784 *
RONKIN, S.M. et al, Bioorganic & Medicinal Chemistry Letters, 2010, vol. 20, pp. 2828-2831 *
TSUGE, O., et al, Tetrahedron, 1973, vol. 29, pp. 1983-1990 *

Also Published As

Publication number Publication date
AU2012357747A2 (en) 2014-08-21
PL2793883T3 (pl) 2018-09-28
HUE038407T2 (hu) 2018-10-29
US9856246B2 (en) 2018-01-02
RS57389B1 (sr) 2018-09-28
DK2793883T3 (en) 2018-07-30
WO2013092711A1 (en) 2013-06-27
EA201491213A1 (ru) 2014-11-28
SI2793883T1 (en) 2018-08-31
LT2793883T (lt) 2018-08-10
ZA201404499B (en) 2015-12-23
HRP20181086T1 (hr) 2018-09-07
KR102000319B1 (ko) 2019-09-27
EP2793883B1 (en) 2018-04-18
EP2793883A1 (en) 2014-10-29
JP2017197564A (ja) 2017-11-02
US9585875B2 (en) 2017-03-07
ME03038B (me) 2018-10-20
TR201808861T4 (tr) 2018-07-23
JP2015504874A (ja) 2015-02-16
PT2793883T (pt) 2018-07-18
EA025356B1 (ru) 2016-12-30
US20140371276A1 (en) 2014-12-18
KR20150000870A (ko) 2015-01-05
AU2012357747A8 (en) 2014-07-24
HK1203810A1 (en) 2015-11-06
CN104220069A (zh) 2014-12-17
CN104220069B (zh) 2018-10-02
SMT201800351T1 (it) 2018-09-13
CY1120403T1 (el) 2019-07-10
AU2012357747A1 (en) 2014-07-10
US20170129881A1 (en) 2017-05-11
ES2676884T3 (es) 2018-07-25
JP6238906B2 (ja) 2017-11-29

Similar Documents

Publication Publication Date Title
AU2012357747B2 (en) TRPM8 antagonists
US11046662B2 (en) 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma
EP2606888A1 (en) Trpm8 antagonists
CN105017242B (zh) 新型联苯杂环类衍生物、其制备方法及其作为药物的用途
US7786155B2 (en) Organic compounds
HK1203810B (zh) Trpm8拮抗剂
HK1235778B (en) 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma
HK1235778A1 (en) 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and asthma

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 27 , PAGE(S) 3642 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME DOMPE' S.P.A., APPLICATION NO. 2012357747, UNDER INID (54) CORRECT THE TITLE TO READ TRPM8 ANTAGONISTS

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 AUG 2014

FGA Letters patent sealed or granted (standard patent)